FARMACOLOGIA E POSSIVEIS INDICAÇOES CLINICAS DA VASOPRESSINA. UMA REVISAO SOBRE UMA ANTIGA E ATUAL DROGA





FARMACOLOGIA E POSSIVEIS INDICAÇOES CLINICAS DA VASOPRESSINA. UMA REVISAO SOBRE UMA ANTIGA E ATUAL DROGA

(especial para SIIC © Derechos reservados)
Apesar de todas as evidências favoráveis da vasopresina, a ausência de dados relacionados a possíveis efeitos colaterais, limita o seu uso em humanos.
barbosaevora9.jpg Autor:
Paulo R. Barbosa Evora
Columnista Experto de SIIC

Institución:
Laboratório de Função Cardiovascular e Endotelial da Divisão de Cirurgia Experimental da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo


Artículos publicados por Paulo R. Barbosa Evora
Coautores
Alfredo José Rodrigues* Eduardo Guilherme Leite** 
Professor Doutor, Universidade de São Paulo, Ribeirão Preto, Brasil*
Estudante de Medicina, Universidade de São Paulo, Ribeirão Preto, Brasil**
Recepción del artículo
25 de Enero, 2006
Aprobación
24 de Febrero, 2006
Primera edición
11 de Julio, 2006
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
A vasopressina, ou hormônio anti-diurético, é um hormônio peptídeo que é sintetizado nos núcleos supraórticos e paraventriculares do hipotálamo e transportado para a hipófise posterior, onde é armazenado. É liberado na circulação por estímulo da osmolalidade aumentada do protoplasma ou como uma resposta baroreflexa a diminuições do volume ou pressões sanguíneos. 1) A liberação de vasopressina é aumentada também por náusea, dor, e outros estímulos. Apesar de ser uma antiga droga a vasopressina tem sido de modo crescente na literatura médica, principalmente relacionando os seus possíveis efeitos terapêuticos na ressuscitação cardiopulmonar e choque circulatório vasoplégico. Esse fato motivou a presente revisão subdividida em itens: 1) Aspectos gerais; 2) Efeitos na circulação coronariana; 3) Efeitos na circulação pulmonar; 4) Efeitos na parada cardíaca; 5) Efeitos na circulação cerebral e morte eencefálica; 6) Utilização terapêutica no choque circulatório e; 7) Utilização terapêutica em cirurgia cardíaca. A vasopressina é um agente pressórico não adrenérgico com significante efeito vasoconstritor, o qual pode ser utilizado, clinicamente, em situações de choque vasoplégico e ressuscitação cardiorespiratória irreversível pelas manobras clássicas. Apesar de todas as evidências favoráveis mencionadas, a ausência de dados relacionados a possíveis efeitos colaterais, limita o seu uso em humanos.

Palabras clave
vasopressina, hormônio anti-diurético


Artículo completo

(castellano)
Extensión:  +/-7.03 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Vasopressin is a peptide hormone that is synthesized in the hypothalamus supraoptic and paraventricular nuclei and transported to the posterior pituitary, where it is stored. It is released into the circulation upon stimulation by increased plasma osmolality or as a baroreflex response to decreases in blood volume or blood pressure. Vasopressin release is also increased by nausea, pain, and other stimuli. The recent medical literature reports its therapeutic effects in cardiopulmonary arrest and vasoplegic circulatory shock. This fact motivated the present review organized in the following items: 1) General aspects; 2) Coronary circulation effects; 3) Lung circulation effects; 4) Cardiac arrest; 5) Effects in the cerebral circulation and encephalic death; 6) Therapeutic use in circulatory shock and; 7) Therapeutic use in heart surgery. Vasopressin is a non adrenergic pressoric agent with significant vasoconstritor effect, which can be clinically used in situations of vasoplegic shock and cardiopulmonary resuscitation irreversible by the classic maneuvers. In spite of all this favorable evidences, the absence of data related to possible side effects, limits its use in humans.

Key words
vasopressin, antidiuretic hormone


Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Farmacología
Relacionadas: Medicina Farmacéutica, Medicina Interna, Nefrología y Medio Interno



Comprar este artículo
Extensión: 7.03 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Paulo Robe Barbosa Evora, Laboratório de Função Cardiovascular e Endotelial da Divisão de Cirurgia Experimental da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, 14105-120, Rua Rui Barbosa 367, Ap. 15, Ribeirão Preto, Brasil
Bibliografía del artículo
1. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979; 236:F321-32.
2. Reid IA, Schwartz J. Role of vasopressin in the control of blood pressure. In: Martini L, Ganong WF, eds. Frontiers in Neuroendocrinology. New York, NY: Raven Press; 1984:177-97.
3. Montani JP, Liard JF, Schoun J, Mohring J. Hemodynamic effects of exogenous and endogenous vasopressin at low plasma concentrations in conscious dogs. Circ Res 1980; 47:346-55.
4. Undesser KP, Hasser EM, Haywood JR, Johnson AK, Bishop VS. Interactions of vasopressin with the area postrema in arterial baroreflex function in conscious rabbits. Circ Res 1985; 56:410-7.
5. Luk J, Ajaelo I, Wong V, Wong J, Chang D, Chou L, Reid IA. Role of V1-receptors in the action of vasopressin on the baroreflex control of heart. Am J Physiol 1993; 265:R524-9.
6. Cowley AW Jr, Monos E, Guyton AC. Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res 1974; 34:505-14.
7. Mohring J, Glanzer K, Maciel JA Jr, Dusing R, Kramer HJ, Arbogast R, Koch-Weser J. Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. J Cardiovasc Pharmacol 1980; 2:367-76.
8. Manning M, Sawyer WH. Antagonists of vasopressor and antidiuretic responses to arginine vasopressin. Ann Intern Med 1982; 96:520-2.
9. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000; 11:406-10.
10. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In Hardman JG, Limbird LE, Gilman AG (eds). Goodman & Gilman's pharmacological basis of therapeutics 9Ed, New York: McGraw Hill, 1996:715-31.
11. Lamping KG, Kanatuska H, Eastham CL, Chilian WM, Marcus ML. Nonuniform vasomotor responses of the coronary microcirculation to serotonin and vasopressin. Circ Res 1989; 65:343-51.
12. Katusic ZS, Shepherd JT, Vanhoutte PM. Vasopressin causes endothelium-dependent relaxations of the canine basilar artery. Circ Res 1984; 55:575-9.
13. Myers PR, Banitt PF, Guerra R Jr, Harrison DG. Characteristics of canine coronary resistance arteries: importance of endothelium. Am J Physiol 1989; 257(2 Pt 2):H603-H610.
14. Maturi MF, Martin SE, Markle D, Maxwell M, Burruss CR et al. Coronary vasoconstriction induced by vasopressin. Production of myocardial ischemia in dogs by constriction of nondiseased small vessels. Circulation 1991; 83:2111-21.
15. García Villalón AL, García JL, Fernández N, Monge L, Gómez B, Diéguez G. Regional differences in the arterial response to vasopressin: role of endothelial nitric oxide. Br J Pharmacol 1996; 118:1848-54.
16. Lee SL, Levitsky S, Feinberg H. Endogenous vasoconstrictor prostanoids: role in serotonin and vasopressin-induced coronary vasoconstriction. J Pharmacol Exp Ther 1991; 258:292-8.
17. Hupf H, Grimm D, Riegger GA, Schunkert H. Evidence for a vasopressin system in the rat heart. Circ Res 1999; 84:365-70.
18. Fernández N, García JL, García Villalón AL, Monge L, Gomes, B, Diéguez, G. Coronary vasoconstriction produced by vasopressin in anesthetized goats. Role of vasopressin V1 and V2 receptors and nitric oxide. Eur J Pharmacol 1988; 342:225-33.
19. Bax WA, Van der Graaf PH, Stam WB, Bos E, Nisato D, Saxena PR. [Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists. Eur J Pharmacol 1995; 285:199-202.
20. Okamura T, Ayajiki K, Fujioka H, Toda N. Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries. J Hypertension 1999; 17:673-8.
21. Evora PR, Pearson PJ, Rodrigues AJ, Viaro F, Schaff HV. Effect of arginine vasopressin on the canine epicardial coronary artery:experiments on V1-receptor-mediated production of nitric oxide. Arq Bras Cardiol. 2003; 80:483-94.
22. Rees DD, Palmer RMJ, Hodson HF, Moncada, S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 1989; 96:418-24.
23. Moore PK, al-Swayeh OA, Chong NWS, Evans RA, Gibson A. L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol 1990; 99:408-12.
24. Palmer RMJ, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophysic Res Comm 1988; 153:1251-6.
25. Kruszynsky M, Lammek B, Manning M. 1-(ß-Mercapto-ß,ß-ciclopentamethylenepropionic acid), 2-(O-methyl)tyrosine arginine vasopressin and 1-(ß-mercapto-ß,ß-ciclopentamethylenepropionic acid) arginine vasopressin, two highly potent antagonists of the vasopressor response to arginine vasopressin. J Med Chem 1980; 23:364-8.
26. Liard JF, Spadone JC. Hemodynamic effects of antagonists of the vasoconstrictor action of vasopressin in conscious dogs. J Cardiovasc Pharmacol 1984; 6:713-19.
27. Sawyer WH, Grzonka, Z, Manning M. Neurohypophyseal peptides. Design of tissue-specific agonists and antagonists. Molec Cell Endocrinol 1981; 22:117-34.
28. Ignarro LJ. Signal transduction mechanisms involving nitric oxide. Biochem Pharmacol 1991; 41:485-90.
29. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 1993; 103:1241-5.
30. Katusic ZS. Endothelial L-arginine pathway and regional cerebral arterial reactivity to vasopressin. Am J Physiol 1992; 262:H1557-H1562.
31. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000; 11:406-10.
32. De Aguilera EM, Via JM, Irurzun A, Martinez, MC, Cuesta MAM, Lluch S. Endothelium-independent contractions of human cerebral arteries in response to vasopressin. Stroke 1990; 21:1689-93.
33. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo, EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57:946-55.
34. Gruetter CA, Barry BK, MacNamara DB, Gruetter DY, Kadwitz PJ, Ignarro LJ. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside, and a carcinogenic nitrosamide. J Cyclic Nucleotide Res 1979; 5:211-24.
35. Leather HA, Segers P, Berends N, Vandermeersch E, Wouters PF. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med. 2002; 2548-52.
36. Morris DC, Dereczyk BE, Grzybowwski M, Martin GB, Rivers EP, Wotsman J, Amico JA. Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation. Acad Emerg Med 1997; 4:878-83.
37. Wenzel V, Lindner KH, Krismer AC, Miller EA, Voleckel, WG, Lingnau W. Repeated administration of vasopressin but not epinephrine maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Circulation 1999; 99:1379-84.
38. Jeu LA, Cheng J. Cardiovascular Pharmacology. Vasopressin: new indications for an old drug Today in Cardiology, August 2001.
39. Faraci FM, Heistad DD. Regulation of large cerebral arteries and cerebral microvascular pressure. Circ Res 1990; 8-17.
40. Chen EP, Bittner HB, Kendall SWH, Vantrigt P. Hormonal and hemodynamic changes in a validated animal model of brain death. Crit Care Med 1996; 24:1352-1359.
41. Novitzky D, Cooper DKC, Wicomb WN. Electrocardiographic, hemodynamic, and endocrine changes occurring during experimental brain death in the Chacma baboon. J Heart Transplant 1984; 4:63-69.
42. Finkelstein I, Toledo-Pereyra LH, Castellanos J. Physiologic and hormonal changes in experimentally induced brain dead dogs. Transplant Proc 1987; 5:4156-4158.
43. Cintra EA, Maciel Junior JA, Araujo S, Castro M, Martins EF. Vasopressin and brain death. Arq Neuro-Psiquiatr 2000, 58:181-7.
44. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro DA, et al. Vasopressin deficiency in vasodilatory septic shock. Crit Care Med 1997; 25:1279-82.
45. Argenziano M, Chen JM, Choudhri AF, Culliname S, Garfein E, Weinberg AD, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998; 1169:973-80.
46. Holmes CL, Walley KR.Vasopressin in the ICU. Curr Opin Crit Care 2004; 10:442-8.
47. Albright TN, Zimmerman MA, Selzman CH. Vasopressin in the Cardiac Surgery Intensive Care Unit. Am J Crit Care 2002; 11:326-30.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618